Neovascularisation of intracranial tumours

  • R. H. Lye
  • S. F. Elstow
  • J. B. Weiss


Extracts from samples of 1 glioblastoma, 8 meningiomas (5 of which were pooled) and pooled samples of 4 acoustic nerve tumours were tested for endothelial-cell-stimulating angiogenesis factor (ESAF). The ex-tracts were separated into fractions of known molecular mass using gel-filtration chromatography. Neo-vascularisation resulting from angiogenic activity was assessed for each fraction using the chick chorioallan-toic (CAM) and chick vitelline membrane (VIM) tests. Angiogenic activity was found in all the samples tested. The activity was present in the dialysate, suggesting that the factor responsible was of low Mr. Some samples were further fractionated on Biogel P2 and activity was demonstrated in fractions of molecular mass 300–600. ESAF activity was easily dissociated from any carrier protein which may have been present. ESAF from other sources has been shown previously to activate fibroblast procollagenase and the meningioma ESAF had the same ability.


angiogenesis endothelial cells intracranial neoplasm neovascularisation tumour angiogenesis factor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumour factor responsible for angiogenesis. J Exp Med 133: 275–288, 1971PubMedCrossRefGoogle Scholar
  2. 2.
    Auerbach R: Angiogenesis-inducing factors: a review. Lymphokines 4: 69–88, 1981Google Scholar
  3. 3.
    Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsburn M: Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223: 1296–1298, 1984PubMedCrossRefGoogle Scholar
  4. 4.
    Weiss JB, Brown RA, Kumar S, Phillips P: Angiogenic factor isolated from tumours: a potential low molecular-weight compound. Brit J Cancer 40: 493–496, 1979PubMedCrossRefGoogle Scholar
  5. 5.
    McAuslan BR, Hoffman H: Endothelium stimulating fac-tor from Walker carcinoma cells. Relation to tumor an-giogenic factor. Expl Cell Res 119: 181–190, 1979CrossRefGoogle Scholar
  6. 6.
    Fenselan A, Watt S, Mello RJ: Tumour angiogenic factor. Purification from the Walker 256 rat tumour. J Biol Chem 256: 9605–9611, 1981Google Scholar
  7. 7.
    Klagsburn M, Knighton D, Folkman J: Tumor angiogenesis activity in cells grown in tissue culture. Cancer Res 36: 110–114, 1976Google Scholar
  8. 8.
    Weiss JB, Elstow SF, Hill CR, McLaughlin B, Davidson EM, Schor A, Ayad SR: Low molecular weight angio-genesis factor: a growth factor not unique to tumours which activates procollagenase. Prog appl Microcirc 4: 76–87, 1984Google Scholar
  9. 9.
    Oyama VI, Eagle H: Measurement of cell growth in tissue culture with a phenol reagent (Folin-Ciocalteau). Proc Soc Exp Biol Med 91: 305–307, 1956PubMedGoogle Scholar
  10. 10.
    Weiss JB, Hill CR, Davis RJ, McLaughlin B, Sedowofia KA, Brown RA: Activation of a procollagenase by low-molecular weight angiogenesis factor. Bioscience Reports 3: 171–177, 1983 (a)PubMedCrossRefGoogle Scholar
  11. 11.
    Weiss JB, Hill CR, McLaughlin B, Elstow S: Potentiating effect of heparin in the activation of procollagenase by a low Mr angiogenesis factor. FEBS Lett 163: 62–65, 1983 (b)PubMedCrossRefGoogle Scholar

Copyright information

© Martinas Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • R. H. Lye
    • 1
  • S. F. Elstow
    • 2
  • J. B. Weiss
    • 2
  1. 1.University Department of NeurosurgeryManchester Royal InfirmaryManchesterEngland, UK
  2. 2.Department of BiochemistryUniversity of ManchesterManchesterEngland, UK

Personalised recommendations